Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FIXX Homology Medicines		$1.18	$0.46 ▼ $17.51	$978.01M	-0.1	390,307 shs	22,300 shs
PRGO Perrigo	$27.20 -0.2%	$26.50	$23.14 ▼ $30.93	$3.75B	0.45	1.45 million shs	454,245 shs
PTCT PTC Therapeutics	$48.77 -0.8%	$48.22	$29.02 ▼ $58.38	$3.90B	0.5	862,349 shs	307,079 shs
RYTM Rhythm Pharmaceuticals	$65.78 -1.7%	$62.82	$40.46 ▼ $69.89	$4.26B	2.26	557,108 shs	628,374 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FIXX Homology Medicines	0.00%	0.00%	0.00%	0.00%	0.00%
PRGO Perrigo	-0.11%	+2.20%	+2.61%	+3.40%	+3.82%
PTCT PTC Therapeutics	-0.77%	-1.57%	-3.79%	+12.79%	+57.33%
RYTM Rhythm Pharmaceuticals	-1.71%	+7.06%	+0.16%	+40.10%	+61.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FIXX Homology Medicines	0.7755 of 5 stars	0.0	0.0	0.0	4.8	0.6	0.8	0.6
PRGO Perrigo	4.8838 of 5 stars	2.1	5.0	4.2	3.5	3.3	1.7	2.5
PTCT PTC Therapeutics	4.3337 of 5 stars	4.3	1.0	0.0	4.4	1.5	0.8	1.3
RYTM Rhythm Pharmaceuticals	3.8184 of 5 stars	3.5	2.0	0.0	4.3	1.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FIXX Homology Medicines	0.00	N/A	N/A	N/A
PRGO Perrigo	2.25	Hold	$33.00	21.32% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	33.28% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$77.31	17.53% Upside

Current Analyst Ratings Breakdown

Latest FIXX, RYTM, PTCT, and PRGO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$84.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00
5/9/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$55.00 ➝ $68.00
5/8/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/7/2025	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$57.00 ➝ $58.00
5/7/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$70.00 ➝ $66.00
5/7/2025	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$113.00 ➝ $112.00
5/7/2025	PTCT PTC Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $67.00
5/7/2025	PTCT PTC Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$50.00 ➝ $40.00

(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FIXX Homology Medicines	$1.16M	0.00	N/A	N/A	$1.26 per share	0.00
PRGO Perrigo	$4.37B	0.86	$5.04 per share	5.40	$31.66 per share	0.86
PTCT PTC Therapeutics	$806.78M	4.79	N/A	N/A	($14.24) per share	-3.42
RYTM Rhythm Pharmaceuticals	$130.13M	32.16	N/A	N/A	$0.35 per share	187.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FIXX Homology Medicines	-$112.96M	-$1.96	N/A	N/A	N/A	-4,779.31%	-102.52%	-74.91%	N/A
PRGO Perrigo	-$171.80M	-$1.31	N/A	8.89	N/A	-4.16%	8.93%	3.87%	8/1/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.49	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)

Latest FIXX, RYTM, PTCT, and PRGO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q2 2025	PRGO Perrigo	$0.59	N/A	N/A	N/A	$1.08 billion	N/A
5/7/2025	Q1 2025	PRGO Perrigo	$0.56	$0.60	+$0.04	-$0.05	$1.09 billion	$1.04 billion
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FIXX Homology Medicines	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	4.26%	N/A	N/A	23 Years
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest FIXX, RYTM, PTCT, and PRGO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/30/2025	PRGO Perrigo	quarterly	$0.29	4.55%	5/30/2025	5/30/2025	6/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FIXX Homology Medicines	N/A	7.25	7.25
PRGO Perrigo	0.82	2.36	1.28
PTCT PTC Therapeutics	N/A	3.89	3.85
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FIXX Homology Medicines	31.32%
PRGO Perrigo	95.91%
PTCT PTC Therapeutics	N/A
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
FIXX Homology Medicines	16.10%
PRGO Perrigo	0.70%
PTCT PTC Therapeutics	5.50%
RYTM Rhythm Pharmaceuticals	6.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FIXX Homology Medicines	7	58.13 million	48.77 million	Optionable
PRGO Perrigo	8,379	137.48 million	136.52 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable

FIXX, RYTM, PTCT, and PRGO Headlines

Recent News About These Companies

Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 1,319 Shares of Stock

1 hour ago | insidertrades.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Alastair Garfield Sells 1,319 Shares

July 3 at 6:41 PM | marketbeat.com

Rhythm Pharmaceuticals Inc News (RYTM) - Investing.com

July 2 at 7:27 PM | investing.com

Adcock, Chiefs blank Rhythm to win 5th straight

July 1 at 6:12 AM | wpsdlocal6.comW

NPSL: Bristol Rhythm fall on the road, close out season with two home games this week

June 30, 2025 | heraldcourier.comH

The UniverSoul Circus brings its 'Rhythm of the World' tour to National Harbor

June 30, 2025 | wusa9.comW

Of Wood, Worship And Wonder: Rhythm Wagholikar On The Rath Yatra Tradition

June 28, 2025 | msn.com

Rhythm & Food community BBQ

June 28, 2025 | kxnet.comK

Rhythm & Roots unveils artist schedule, puts single-day tickets on sale

June 28, 2025 | heraldcourier.comH

Rhythm & Rally offer pickleball for Neurodivergent kids

June 28, 2025 | 41nbc.com4

Rhythm Pharmaceuticals (NASDAQ:RYTM) Earns Market Outperform Rating from JMP Securities

June 28, 2025 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (RYTM) - Yahoo Finance

June 27, 2025 | finance.yahoo.com

Rhythm Pharmaceuticals: Growth Is Expected To Go Parabolic

June 27, 2025 | seekingalpha.com

Rhythm and Blues Show

June 27, 2025 | deltanews.tvD

Rhythm Pharmaceuticals Announces Late-Breaking Abstracts for ENDO 2025 Featuring Pivotal Phase 3 and Phase 2 Trial Results on Acquired Hypothalamic Obesity - Nasdaq

June 27, 2025 | nasdaq.com

Rhythm Pharmaceuticals' (RYTM) "Market Outperform" Rating Reiterated at JMP Securities

June 26, 2025 | marketbeat.com

Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

June 25, 2025 | finanznachrichten.de

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

June 25, 2025 | globenewswire.com

Avior Wealth Management LLC Invests $243,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 24, 2025 | marketbeat.com

22,192 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Bought by Assenagon Asset Management S.A.

June 18, 2025 | marketbeat.com

SG Americas Securities LLC Buys Shares of 19,667 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

June 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
These 3 Dividend Stocks Combine Strong Yields With Upside
By Chris Markoch | June 20, 2025
View These 3 Dividend Stocks Combine Strong Yields With Upside

FIXX, RYTM, PTCT, and PRGO Company Descriptions

Homology Medicines NASDAQ:FIXX

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Perrigo NYSE:PRGO

$27.20 -0.06 (-0.22%)

Closing price 07/3/2025 03:30 PM Eastern

Extended Trading

$27.21 +0.01 (+0.04%)

As of 07/3/2025 04:20 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

PTC Therapeutics NASDAQ:PTCT

$48.77 -0.38 (-0.77%)

Closing price 07/3/2025 03:28 PM Eastern

Extended Trading

$48.77 0.00 (0.00%)

As of 07/3/2025 04:20 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Rhythm Pharmaceuticals NASDAQ:RYTM

$65.78 -1.15 (-1.71%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$65.74 -0.04 (-0.06%)

As of 07/3/2025 04:20 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time